00:57 , Feb 27, 2016 |  BC Extra  |  Politics & Policy

CFDA issues import testing rules

China FDA now requires all imported drugs to comply with the China Pharmacopeia (ChP) standards in addition to the registration standards of the exporting country, according to life sciences law firm Sidley Austin LLP. Imports...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Ligand, TG Therapeutics deal

Ligand granted TG exclusive, worldwide rights to develop and commercialize Ligand’s interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors. The program is in preclinical development to treat B cell malignancies and undisclosed autoimmune diseases. Ligand will receive...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

CollabRx management update

CollabRx Inc. (NASDAQ:CLRX), San Francisco, Calif.   Business: Bioinformatics   Hired: Clifford Baron as VP and COO, formerly director of biology product marketing, business development and professional services at Accelrys Inc.  ...
07:00 , Sep 5, 2013 |  BC Innovations  |  Targets & Mechanisms

Epilepsy narrows down

A spate of human genetic studies has shed light on the root causes of idiopathic focal epilepsy, a common childhood form of the disease. The studies suggest that a group of epilepsies and encephalopathies marked...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Company News

Corning Inc., National Institutes of Health, Skoll Foundation, U.S. Agency for International Development (USAID), U.S. Centers for Disease Control and Preventio

FDA established a public-private partnership to develop its CD-3 device to identify counterfeit or substandard anti-malarial medicines. In 2013-14, U.S. Pharmacopeia, with funds from USAID and the multi-agency President's Malaria Initiative led by USAID and...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Pharmacopeia, Texas Biotech deal

The companies will identify drug candidates for targets involved in diseases of the vascular endothelium, such as stroke and asthma. TXB will have access to PCOP's small molecule combinatorial chemistry libraries to identify lead compunds...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Pharmacopeia, Schering-Plough deal

The companies extended through 1998 their 1994 collaboration to discover small molecule compounds for asthma and cancer and expanded the research to include hepatitis using PCOP's combinatorial chemistry and high throughput screening technology (see BioCentury,...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Ligand, Retrophin deal

Ligand received a $1.4 million milestone payment from Retrophin under a 2012 deal granting Retrophin an exclusive, worldwide sublicense to RE-021 . Ligand said the payment was a "time-based milestone." Under the deal, Ligand is...
08:00 , Feb 25, 2013 |  BioCentury  |  Regulation

China's Bottleneck

China has invested billions in life science research over the past decade, and Western companies have flocked to the region to open new research facilities. The investment is crucial to stimulating economic growth as well...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

Dinaciclib: Phase IIb/III started

Ligand began a Phase IIb/III trial to evaluate dinaciclib in patients with refractory CLL. The trial start triggers a $2 million milestone payment from partner Merck under a deal to develop dinaciclib. Ligand said it...